US Price Negotiation Process: Is Case-By-Case Politically Sustainable?
• By Michael McCaughan
HHS appears to have the advantage on Medicare drug pricing, but the new ‘negotiation’ process will inevitably involve outside pressure that may shift the balance. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
